Henn Matthew R 4

4 · Seres Therapeutics, Inc. · Filed Feb 18, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Seres (MCRB) CSO Matthew Henn Sells 89 Shares

What Happened

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics (MCRB), had 239 restricted stock units (RSUs) convert into 239 shares on Feb 15, 2026. To cover taxes tied to that vesting, Henn sold 89 shares in the open market at $8.47 each for $754 and had 239 shares reported as surrendered/converted (reported as derivative dispositions at $0).

Key Details

Transaction date: February 15, 2026; Form 4 filed February 18, 2026.
Open-market sale: 89 shares at $8.47/share — proceeds $754.
RSU conversion: 239 shares acquired via conversion of RSUs (reported with price N/A).
Withholding/net settlement: 141 shares and 98 shares reported as disposed at $0 (derivative-related dispositions totaling 239 shares).
Plan/footnotes: Sales were effected under a Rule 10b5-1 plan (adopted April 13, 2023) solely to cover taxes related to RSU vesting. RSUs vest per the disclosed schedule (25% vested Feb 15, 2024 and Feb 15, 2025; remainder vest quarterly thereafter; RSUs convert to one share each).
Shares owned after transaction: not specified in the provided excerpt.
Filing timeliness: Form 4 filed Feb 18; the report does not indicate a late filing flag.

Context

These entries reflect RSU settlement and related tax-covering actions (10b5-1 sale and shares withheld/surrendered). Such transactions are commonly routine tax-withholding events rather than directional bets on the stock. The derivative entries indicate conversion/settlement of RSUs and withholding rather than a traditional option exercise for cash.

Form 4

Period: 2026-02-15

See Remarks

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-15+239→ 7,766 total
Sale
Common Stock
[F2]
2026-02-15$8.47/sh−89$754→ 7,677 total
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-02-15−141→ 563 total
→ Common Stock (141 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-02-15−98→ 780 total
→ Common Stock (98 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
[F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
[F3]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
[F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Signature

/s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn|2026-02-18

1 file